key: cord-0277456-ykq03uc8 authors: Banho, C. A.; Sacchetto, L.; Campos, G. R. F.; Bittar, C.; Possebon, F. S.; Ullmann, L. S.; Marques, B. d. C.; da Silva, G. C. D.; Moraes, M. M.; Parra, M. C. P.; Negri, A. F.; Boldrin, A. C.; Barcelos, M. D.; dos Santos, T. M. I. L.; Milhim, B. H. G. d. A.; Rocha, L. C.; Dourado, F. S.; dos Santos, A. L.; Ciconi, V. B.; Patuto, C.; Versiani, A. F.; da Silva, R. A.; Lobl, E. E. d. O.; Hernandes, V. M.; Zini, N.; Pacca, C. C.; Estofolete, C. F.; Ferreira, H. L.; Rahal, P.; Araujo, J. P.; Cohen, J. A.; Althouse, B. M.; Vasilakis, N.; Nogueira, M. L. title: Effects of SARS-CoV-2 P.1 introduction and the impact of COVID-19 vaccination on the epidemiological landscape of Sao Jose Do Rio Preto, Brazil date: 2021-07-31 journal: nan DOI: 10.1101/2021.07.28.21261228 sha: 452b26c9fdd46f6cc2d234c11de26609257a43ba doc_id: 277456 cord_uid: ykq03uc8 The emergence of the new Brazilian variant of concern, P.1 lineage (Gamma), raised concern about its impact on the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. Using 272 whole-genome sequences combined with epidemiological data, we showed that P.1 introduction in Sao Jose do Rio Preto, Sao Paulo, Brazil, was followed by the displacement of eight circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection. Our findings support that the P.1 variant is associated with an increase in mortality risk and severity of COVID-19 cases in younger aged groups, which corresponds to the unvaccinated population at the time. Moreover, our data highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of lives worldwide 1 , and with its rapid spread and evolution, variants have emerged and continue to emerge globally 2 . Currently, SARS-CoV-2 variants that present a threat to global health are classified as Variants of Interest (VOIs) and Variants of Concern (VOCs) 3 . To date, all VOCs are descendants of the SARS-CoV-2 strain containing a S: D614G mutation, which is associated with increased viral fitness through enhancement of viral load in the upper respiratory tract, favoring viral spread and transmission 4, 5 . As of July 2021, four reported lineages had been defined as VOCs: B.1.1.7 (Alpha), first detected in the United Kingdom (U.K.) in December 2020, has been associated to enhanced transmissibility, higher severity of disease 6, 7 , and lower neutralization potential by vaccine and convalescent sera 8 The Brazilian VOC, P.1 lineage, emerged in Manaus city, the capital of Amazonas state, in November 2020 15 and rapidly spread throughout Brazil and more than 60 countries 2 . As P.1 emerged after a period of rapid genetic diversification 15 , it has accumulated 17 nonsynonymous mutations, ten of which are located in the S protein 13, 15 , of which K417T: E484K: N501Y are of biological importance 16, 17 . Recent studies have reported that P.1 lineage presents an increase in ACE2 receptor affinity due to the presence of the N501Y mutation 16, 18 , which significantly impacts its transmissibility rate, shown to be 1.4-2.2-fold higher than the wild type strain 13 . Moreover, P.1 also exhibited a reduction of anti-RBD antibody neutralization 19 , and it has been implicated in breakthrough infections of vaccinated individuals as well as reinfections All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint 20, 21, 22 . Although several studies documented P.1's increased transmissibility 15, 23 and immune evasion 20, 22, [24] [25] [26] , little is known about its association with the severity of COVID-19 disease and mortality risk, which is crucial to better understand and mitigate the severe impact of the ongoing pandemic. In addition to P.1's emergence and dissemination, Brazil has faced a slow vaccination roll-out, which contributed to the prolonging of the pandemic and the emergence of additional [28] [29] [30] [31] [32] [33] , the impact of slow vaccination rates on the circulation and spread of VOCs on the epidemiological profiles at the national and local level is still unclear. Here, we report the rapid spread of the P.1 variant following its introduction and dissemination in São José do Rio Preto, Brazil, and show that this event was associated with a change in the epidemiological profile, with increased numbers of severe COVID-19 cases and deaths, especially in the unvaccinated population. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A time-trend analysis was performed using a seven-day moving average of notified cases, severe cases, and deaths related to COVID-19 in the RHD XV from March 2020 to May 2021. The data were retrieved from the Public Health System and received from the Reporting Disease Information System (SINAN), using mild respiratory syndrome (e-SUS) and severe acute respiratory syndrome (SRAG) cases databases. Nasopharyngeal swab samples of residents of SJdRP and nearby cities tested at HB by molecular diagnosis in the COVID-19 routine diagnosis with a positive diagnostic for COVID- 19 were obtained between October of 2020 and June of 2021. The total RNA was extracted from 140 µL of nasopharyngeal swab samples, using QIAamp Viral RNA Mini Kit (QIAGEN, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint Hilden, Germany), following the manufacturer's instructions. SARS-CoV-2 RNA investigation was performed by one-step real-time polymerase chain reaction (RT-qPCR) using primers and probes targeting the envelope (E), the nucleocapsid (N) region of the SARS-CoV-2 genome, and the human RNAse P according to GeneFinder COVID-19 Plus RealAmp Kit (OSANG Healthcare, KOR) (the manufacturer does not provide sequences of the primers and probe) 34 . The RT-qPCR was conducted in a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, USA) with the following conditions: 50°C for 20 minutes for the reverse transcription, 95°C for five minutes for denaturation, followed by 45 cycles of denaturation at 95°C for 15 seconds, and annealing at 58°C for 60 seconds The results were analyzed in Whole-genome sequencing was performed using Next-Generation Sequencing (NGS) technology. The cDNA synthesis, whole-genome amplification, and library preparation were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint The quality of FASTQ sequencing data was checked using FastQC software v0.11.9 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc), and trimming was performed in Geneious Prime v. 2021.1 (https://www.geneious.com/), using the plugin BBDuk v. 37.25, to remove primer sequences, adapters, and low-quality bases. A minimum Phred score of Q30 35 and a minimal read length of 75 base pairs (bp) were used. The cleaned paired-end reads were mapped against the hCoV-19/Wuhan/WIV04/2019 (EPI_ISL_402124) genome, available at EpiCoV in GISAID database 36 (https://www.gisaid.org/), considering a minimum 50 bp overlap, minimum identity of 90% and maximum mismatches of 10% per read 37 . SNPs were identified using default settings and minimum coverage of five reads per site. The genomes were submitted to Pangolin COVID-19 Lineage Assigner Tool 2 to confirm the variant classification (https://pangolin.cog-uk.io/). A database was created with SARS-CoV-2 identified lineages, location/municipality origin, and month of the collected sample. Shapefiles of the areas were downloaded, and maps were created using the QGIS software version 3.8.2 (http://qgis.org). The datasets used for the phylogenetic analysis included 780 Brazilian SARS-CoV-2 Brazilian complete genomes sequences and the reference genome hCoV-19/Wuhan/WIV04/2019 (EPI_ISL_402124) retrieved from the GISAID database (https://www.gisaid.org/) (Supplementary Table 6 ). The nucleotide sequences were aligned using MAFFT multiple sequence alignment software version 7.271 38 . Time-scale phylogenetic trees using the Maximum-likelihood (ML) method were reconstructed in IQ-TREE v. 2.0.3 39 , using the best-fit model of nucleotide substitution, according to Bayesian Information Criterion (BIC), inferred by ModelFinder application 40 . The reliability of branching patterns was tested using Aproximate likelihood-ratio test (aLRT) 41 . To investigate the temporal signal from the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint ML tree, we regressed root-to-tip genetic distances against sample collection dates using TempEst v 1.5.1 (http://tree.bio.ed.ac.uk) 42 . Estimation of the effective reproductive number (Reff) for SARS-CoV-2 over the study period was carried out using the package EpiEstim 43 in R version 4.0.4 44 . Detailed methods can be found in the documentation of the EpiEstim package. We fit the time-varying Reff assuming a parametric serial interval with mean and standard deviation of five days 45 using a 21-day sliding window. To assess potential shifts in severity, we calculate the percentage of all cases that are severe for all age groups and for those 70 and older. We compare the proportion of deaths, non-severe, and severe cases by age to look for qualitative shifts in age distributions due to changing transmissibility or virulence of the changing variants and any potential vaccine effects. To assess the magnitude of increases in deaths as a function of P.1 prevalence, we fit both Poisson and Negative Binomial models to calculate incidence rate ratios for death by age adjusting for the count of tests performed on that day. Finally, we include an index of social mobility 46 to track time spent away from the cellphone's predominant nighttime location. For each age groups, the proportion of cases, severe cases, and deaths in that age group relative to people aged under 60 (the age cutoff for the vaccine rollout) was calculated (a) for the period up until the start of the vaccine rollout for that age group, and (b) for the period starting from two weeks after the end of vaccine rollout for that age group and ending on 29 May 2021. For example, if there were 60% as many deaths in people aged 90+ compared to people aged under 65 before the vaccine rollout began, and 30% as many deaths in people aged 90+ compared to under 65 after the vaccine rollout ended, then the change in proportion of deaths would be -50%. Coverage was calculated as the number of doses divided by target population size divided by two (since two doses are required for full coverage). An ordinary least squares fit was performed using Python 3.8 (https://www.python.org/), stats models All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint v0.12.2 (https://www.statsmodels.org/stable/index.html) to calculate the slope of best fit between the vaccine coverage and the change in proportion of each of cases, severe cases, and deaths, with the intercept fixed at zero. Table 1 ). Samples were obtained from 165 female (54%) and 141 male patients (46%), with an average age of 43 years (age range of eight months old to 91years-old). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint SARS-CoV-2 viral lineages (sequences obtained in this study and available at GISAID database) were classified using Pangolin 2 showing that the most prevalent lineages circulating in SJdRP were classified into B.1.1.28 (n=16, 5.6%), N.9 (n=13, 4.6%), P.2 (n=31, 11%), P.1 (n=205, 72.4%) and others (which includes B.1, B.1.1, B.1.2, B.1.1.373, B.1.1.33, B.1.1.332, B.1.1.7 and P.1.1(n=18, 6.3%)) ( Supplementary Tables 2 and 3) . The variant prevalence changed over time, from seven lineages co-circulating in October and November 2020, with a predominance of N.9 (28.5%) and B.1.1.28 (28.5%) to eight lineages in January and February 2021. Additionally, a shift in the prevalence of variants was observed, represented by a fourfold decrease in N.9 frequency (7.3% of sequenced genomes) and an increase of P.2 variant frequency (61% of sequenced genomes). Moreover, in January 2021, P.1 lineage was first detected and contributed to changing the landscape of circulating variants in SJdRP (Fig. 1d) and surrounding cities ( Supplementary Fig. 2, Supplementary Tables 4 and 5) for the subsequent months. Critically, following P.1 introduction, a rapid increase in prevalence was observed, reaching more than 96% of the sequenced genomes from March to June, thus replacing P.2 and other lineages (Fig. 2) . In April 2021, VOC B.1.1.7 was first detected in SJdRP, and despite its low frequency, it was the only variant identified in May and June together with P.1.1 in addition to P.1 (Fig. 1d) . Similarly, a complete replacement of other variants by P.1 was also observed in neighboring municipalities of SJdRP, administered by the Regional Health Division (RHD XV), for which SJdRP serves as the main health center ( Supplementary Fig. 2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We performed a maximum likelihood phylogeographic analysis using a dataset (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint and 10 were sequences retrieved from the GISAID database (Supplementary Table 6 ). Our genomic surveillance indicates that multiple introduction events of different SARS-CoV-2 lineages occurred in SJdRP from several Brazilian regions (Fig. 2) . The B.1.1.28 variant (n=16), the ancestral lineage of P.1 and P.2, was introduced in SJdRP several times over at least five months. The most prevalent lineages, P.1 (n= 205) and P.2 (n= 31) formed a well-supported group (aLRT= 99.8 and 92.5, respectively), including sequences from four Brazilian geographic regions, further supporting the notion of repeated strain introductions into the area (Fig. 2 ). Due to a large number of SARS-CoV-2 P.1 sequences detected in our genomic surveillance, we performed a more targeted phylogenetic analysis of all sequences sampled solely from SJdRP and the surrounding area ( Supplementary Fig. 3 , Supplementary Tables 7 and 8). P.1 sequences formed a single well-supported group (aLRT= 100) clustered most closely with B.1.1.28 sequences, the parental lineage of P.1 (Fig 3) . The first detection of P.1 strains in SJdRP was on 26 January 2021, followed by a rapid increase in its prevalence over other variants. The Fig. 3 shows the dominance of P.1, which displaced all the other variants circulating in SJdRP in less than two months (from March 2021). Root-to-tip analyses confirmed that P.1 was the most divergent variant (Fig. 3) . Interestingly, P.1 samples collected at the same period displayed different divergence patterns, which could indicate a diversification process in the P.1 variant circulating in SJdRP (Fig. 3) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint Phylogenetic tree reconstructed using GTR+F+R2 as nucleotide substitution model. The reliability of branching patterns was tested using Approximate Likelihood-ratio test (aLRT). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint Deaths showed a marked increase as variant P.1 became dominant (Fig. 4a) , increasing by 162% (95% CI: 127, 214) when comparing July-September 2020 to March-April 2021. While the over 70 years of age group accounted for most deaths across the epidemic, shifts were seen from older to younger age groups as P.2 waned and P.1 dominated (Fig. 4b) . Cases per 100,000 fluctuated across March 2020 to June 2021 with corresponding estimates of Reff (Fig. 5a, b) . Peaks in cases and Reff were seen in July-August 2020, November 2020, January 2021, and the highest peaks in March and April 2021, followed by reduced social isolation index (Fig. 5a, b) and the rise in dominance of P.1 from March 2021. Non-severe cases were nearly 10-fold higher than severe cases during most of the time of the pandemic, however, an increase of 127% (95% CI: 105, 152) of severe cases was seen in March 2021, corresponding to the rise of P.1 (Fig. 5c, d) . Proportionally, the largest increase in severe cases was seen in those under 70 years old (109% increase comparing January to March 2021; 95% CI: 78,149) as opposed to those over 70, which had a 19% (95% CI: 7, 33) increase ( Supplementary Fig. 4 ). Negative binomial regressions were far superior by AIC than Poisson models. Incidence rate ratios (IRRs) for death ranged from 1.3 (95% CI: 0.63, 2.62) for those aged 30-34 to 2.36 (95% CI: 1.68, 3.49) for those aged 45 to 49 (Fig. 6a) indicating that people aged from 45 to 69 present higher mortality rate due to P.1 infection, likely due to less vaccination coverage by the time of the study (Fig. 6a) . Additionally, daily surveillance of the available Intensive Care Unit (I.C.U.) beds for COVID-19 patients in SJdRP revealed that the occupancy rate reached 100% only in a few days in March 2021, corresponding to the increase of P.1 prevalence and the number of severe cases ( Supplementary Fig. 5) . Nevertheless, as no collapse in the healthcare system was verified, most deaths observed from March 2021 are probably linked to a more severe outcome of P.1 infection than lack of proper medical care. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint CoronaVac and AstraZeneca vaccines were rolled out to people in descending age order, beginning with those aged over 90 years-old on 2 February 2021. To estimate the impact of vaccination, we compared the proportion of cases, severe cases, and deaths in each age group before the rollout (for that age group) versus two weeks after the rollout onwards. A line with a fixed intercept was fit to these changes in proportion, such that a slope of -1 corresponds to one case, severe case, or death being averted per person vaccinated. As shown in Fig. 6b , vaccination was associated with a moderate reduction in the number of cases (best-fit slope -0.21, 95% CI: -0.03, -0.39). However, it was associated with a pronounced reduction in severe cases (-0.55, 95% CI: -0.34, -0.76) and deaths (-0.58, 95% CI: -0.39, -0.77) (Fig. 6c, d) . A slope of less than -1 for deaths, for example, would imply that more than one death is averted per person vaccinated; this would be the case if, for example, people who are vaccinated not only have significantly lower mortality rates if infected but if they also have lower rates of transmission, which preferentially reduces infection rates among unvaccinated people in the same age group (herd immunity). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For more than eighteen months, the world has lived amid a pandemic, with an alarming number of cases and deaths and devastating consequences in all sectors of society. Nevertheless, the current situation in some countries is encouraging, with the number of cases and deaths decreasing rapidly following mass vaccination. Unfortunately, Brazil remains to be an epicenter of SARS-CoV-2 transmission due to the persistent absence of control measures and low vaccination rates 47 . From the first recorded case in February 2020 to July 2021, Brazil recorded more than 19.5 million laboratory-confirmed cases with more than 549 thousand deaths 47 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint We demonstrate that a clade replacement event driven by the introduction of P.1 lineage was able to change the epidemiological landscape of COVID-19 in the municipality. The detection and prevalence of P.1 led to a prominent peak in the total cases and deaths recorded in Furthermore, our results highlight the urgency of rapid and thorough vaccination in all age groups. We showed a pronounced reduction in severe cases and deaths in age groups that have received both doses of SARS-CoV-2 vaccines, meaning that for each vaccinated person, more than one death can be averted, not only due to lower mortality risk, but also due to lower transmission rates for unvaccinated people (herd immunity). In fact, studies have been reported that besides the protective effect of vaccines against SARS-CoV-2 variants, mainly in severe cases 28, 29, 31, 32, 58, 59 , vaccination can reduce the viral load in infections occurring 12-37 days after the first dose 60 , therefore suppressing virus spread. Thus, if efficient vaccination measures are taken rapidly, it is possible to lower the transmission rate, and the mortality risk, for all age groups. Moreover, a rapid and efficient vaccination scenario is essential to reduce the virus divergence, and thus, the emergence of new and more concerning SARS-CoV-2 variants can drive new clade replacement events. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Global situation (2021) Lineage Assignment in an Emerging Pandemic As an Epidemiological Tool WHO. Tracking SARS-CoV-2 variants Spike mutation D614G alters SARS-CoV-2 fitness SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies The basis of a more contagious 501Y.V1 variant of SARS-CoV-2 Neutralisation of SARS-CoV-2 lineage P . 1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine : an immunological study Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil Mild symptomatic sars-cov-2 p.1 (b.1.1.28) infection in a fully vaccinated 83-year-old man Sars-cov-2 reinfection caused by the p.1 lineage in araraquara city, sao paulo state Characterization of a new SARS-CoV-2 variant that emerged in Brazil Proc. Natl. Acad. Sci Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization Antibody evasion by the P.1 strain of SARS-CoV-2 SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies Doses aplicadas de vacinas contra COVID-19, segundo as UFs. e municípios, Brasil, 2021. Ministério da Saúde do Brasil Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK TM COVID-19 Plus RealAmp Kit. Instructions for Use Base-calling of automated sequencer traces using phred. II. Error probabilities Data, disease and diplomacy: GISAID's innovative contribution to global health Tracking SARS-CoV-2 in sewage: Evidence of changes in virus variant predominance during COVID-19 pandemic Multiple sequence alignment, interactive sequence choice and visualization IQ-TREE: A fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies Fast model selection for accurate phylogenetic estimates Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen) EpiEstim: A Package to Estimate Time Varying Reproduction Numbers from Epidemic Curves R: A language and environment for statistical computing. R: A language and environment for statistical computing. R Foundation for Statistical Computing Estimates of serial interval for COVID-19: A systematic review and meta-analysis No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Available at Detection of potential new SARS-CoV-2 Gamma-related lineage in Tocantins shows the spread and ongoing evolution of P . 1 in Brazil Sudden rise in COVID-19 case fatality among young and middle-aged adults in the south of Brazil after identification of the novel B.1.1.28.1 (P.1) SARS-CoV-2 strain: analysis of data from the state of Parana Viral immunogenicity determines epidemiological fitness in a cohort of DENV-1 infection in Brazil Population dynamics of DENV-1 genotype V in Brazil is characterized by co-circulation and strain/lineage replacement Establishment and Lineage Replacement of H6 Influenza Viruses in Domestic Ducks in Southern China Dengue-1 Virus Clade Replacement in Thailand Associated with Enhanced Mosquito Transmission Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas Selection for Virulent Dengue Viruses Occurs in Humans and Mosquitoes Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted All SARS-CoV-2 genomes generated and analyzed in this study are available at EpiCoV database in GISAID The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO)" grant 1U01AI151807 awarded to NV by the National Institutes of Health (NIH/USA). MLN, PR, JPAJ are CNPq Research Fellows. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript D. carried out the genome sequencing. C.A.B. performed genome assembling All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Cell Host Microbe (2021). doi:10.1016/j.chom.2021.04.007 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 31, 2021. The authors declare no competing interests.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 31, 2021. ; https://doi.org/10.1101/2021.07.28.21261228 doi: medRxiv preprint